Anti -Peripheral Myelin Protein 22, CT (PMP22, PMP-22, Growth Arrest-specific Protein 3, GAS-3, GAS3)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 17; NC_000017.10 (15133094..15168674, complement). Location: 17p12

Polyclonal

Rabbit

Recognizes human PMP22.

Affinity Purified
Purified by immunoaffinity chromatography.

Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.05% sodium azide.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-PMP22 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

PMP22 is a major component of myelin expressed in the compact portion of essentially all myelinated fibers in the peripheral nervous system and is produced predominantly by Schwann cells. Studies in injured nerve suggested a role during Schwann cell growth and differentiation. PMP22 is expressed in cranial nerves but not in the mature central nervous system. Studies suggest a possible role of the PMP22 gene in the development of neoplasia in patients with neurofibromatosis and in the myelin degenerative Charcot-Marie-Tooth disease linked to chromosome 17p.

Antibodies; Abs to Myelin

Immunohistochemistry (IHC)

Suitable for use in Immunohistochemistry.
Dilution: Immunohistochemistry (Formalin fixed paraffin embedded): 5ug/ml

17,891 Da[Similar Products]

peripheral myelin protein 22

peripheral myelin protein 22; growth arrest-specific protein 3

Peripheral myelin protein 22

GAS3; PMP-22; GAS-3??[Similar Products]

PMP22_HUMAN

This gene encodes an integral membrane protein that is a major component of myelin in the peripheral nervous system. Studies suggest two alternately used promoters drive tissue-specific expression. Various mutations of this gene are causes of Charcot-Marie-Tooth disease Type IA, Dejerine-Sottas syndrome, and hereditary neuropathy with liability to pressure palsies. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

PMP22: Might be involved in growth regulation, and in myelinization in the peripheral nervous system. Defects in PMP22 are the cause of Charcot-Marie-Tooth disease type 1A (CMT1A); also known as hereditary motor and sensory neuropathy IA. CMT1A is a form of Charcot-Marie- Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1A inheritance is autosomal dominant. Defects in PMP22 are a cause of Dejerine-Sottas syndrome (DSS); also known as Dejerine-Sottas neuropathy (DSN) or hereditary motor and sensory neuropathy III (HMSN3). DSS is a severe degenerating neuropathy of the demyelinating Charcot-Marie- Tooth disease category, with onset by age 2 years. DSS is characterized by motor and sensory neuropathy with very slow nerve conduction velocities, increased cerebrospinal fluid protein concentrations, hypertrophic nerve changes, delayed age of walking as well as areflexia. There are both autosomal dominant and autosomal recessive forms of Dejerine-Sottas syndrome. Defects in PMP22 are a cause of hereditary neuropathy with liability to pressure palsies (HNPP); an autosomal dominant disorder characterized by transient episodes of decreased perception or peripheral nerve palsies after slight traction, compression or minor traumas. Defects in PMP22 are the cause of Charcot-Marie-Tooth disease type 1E (CMT1E); also known as Charcot-Marie- Tooth disease and deafness autosomal dominant. CMT1E is an autosomal dominant form of Charcot-Marie-Tooth disease characterized by the association of sensorineural hearing loss with peripheral demyelinating neuropathy. Defects in PMP22 may be a cause of inflammatory demyelinating polyneuropathy (IDP). IDP is a putative autoimmune disorder presenting in an acute (AIDP) or chronic form (CIDP). The acute form is also known as Guillain-Barre syndrome. Belongs to the PMP-22/EMP/MP20 family.

Protein type: Membrane protein, multi-pass; Membrane protein, integral; Cell cycle regulation; Cell adhesion

Chromosomal Location of Human Ortholog: 17p12

Cellular Component: compact myelin; tight junction; integral to membrane; plasma membrane

Molecular Function: protein binding

Biological Process: cell death; negative regulation of cell proliferation; myelin formation; synaptic transmission; bleb formation; peripheral nervous system development

Disease: Charcot-marie-tooth Disease, Demyelinating, Type 1a; Neuropathy, Hereditary, With Liability To Pressure Palsies; Hypertrophic Neuropathy Of Dejerine-sottas; Charcot-marie-tooth Disease And Deafness; Roussy-levy Hereditary Areflexic Dystasia; Guillain-barre Syndrome, Familial

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.